U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07265739) titled 'Losartan and Paclitaxel in PROC' on Nov. 23.
Brief Summary: The purpose of this Phase II study is to measure the effects of a combination of study drugs, losartan and paclitaxel, on platinum resistant ovarian cancer.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Platinum Resistant Ovarian Cancer
Intervention:
DRUG: losartan
Treatment with losartan will be administered orally once daily starting on day 1 of every 21-day cycle and will be taken continuously throughout the cycle. Losartan is administered at 25 mg a day for the first 7 days of cycle 1. Losartan may be increased to 50 mg daily on day 8 if syst...